Green Valley Investors LLC Has $81.12 Million Stake in Stryker Corporation (SYK)
Green Valley Investors LLC lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 3.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 584,504 shares of the medical technology company’s stock after selling 22,882 shares during the quarter. Stryker Corporation comprises approximately 4.0% of Green Valley Investors LLC’s portfolio, making the stock its 11th biggest position. Green Valley Investors LLC owned about 0.16% of Stryker Corporation worth $81,117,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in the company. Nelson Roberts Investment Advisors LLC raised its position in Stryker Corporation by 2.3% in the first quarter. Nelson Roberts Investment Advisors LLC now owns 56,007 shares of the medical technology company’s stock worth $7,373,000 after acquiring an additional 1,240 shares in the last quarter. Xact Kapitalforvaltning AB raised its position in Stryker Corporation by 13.9% in the first quarter. Xact Kapitalforvaltning AB now owns 52,254 shares of the medical technology company’s stock worth $6,879,000 after acquiring an additional 6,393 shares in the last quarter. Pictet Asset Management Ltd. raised its position in Stryker Corporation by 34.0% in the first quarter. Pictet Asset Management Ltd. now owns 978,677 shares of the medical technology company’s stock worth $128,843,000 after acquiring an additional 248,476 shares in the last quarter. Carnick & Kubik Group LLC purchased a new position in Stryker Corporation in the first quarter worth $1,016,000. Finally, Swiss National Bank raised its position in Stryker Corporation by 22.1% in the first quarter. Swiss National Bank now owns 1,502,071 shares of the medical technology company’s stock worth $197,748,000 after acquiring an additional 272,300 shares in the last quarter. Institutional investors and hedge funds own 74.13% of the company’s stock.
Several research analysts have issued reports on the company. Cowen and Company reiterated a “buy” rating and issued a $160.00 price objective (up previously from $150.00) on shares of Stryker Corporation in a research report on Sunday, July 30th. Zacks Investment Research cut Stryker Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. BidaskClub upgraded Stryker Corporation from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Royal Bank Of Canada increased their price objective on Stryker Corporation from $140.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $148.00 price objective on Stryker Corporation and gave the stock a “hold” rating in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $146.78.
In related news, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction on Friday, August 4th. The stock was sold at an average price of $146.36, for a total value of $731,800.00. Following the transaction, the insider now directly owns 88,207 shares in the company, valued at approximately $12,909,976.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Floyd sold 19,305 shares of Stryker Corporation stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total value of $2,790,730.80. The disclosure for this sale can be found here. Insiders sold a total of 25,429 shares of company stock worth $3,686,927 over the last 90 days. Insiders own 7.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/05/green-valley-investors-llc-has-81-12-million-stake-in-stryker-corporation-syk.html.
Shares of Stryker Corporation (NYSE SYK) opened at 145.97 on Thursday. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84. The firm has a market cap of $54.60 billion, a price-to-earnings ratio of 32.58 and a beta of 0.80. The company’s 50 day moving average price is $142.31 and its 200-day moving average price is $139.81.
Stryker Corporation (NYSE:SYK) last issued its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.02. The business had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.98 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.39 EPS. Equities analysts expect that Stryker Corporation will post $6.46 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be issued a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s payout ratio is 37.95%.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.